Swiss drugmaker Roche searching for new site to trial Covid-19 pill as virus prevalence in UK falls

The pharmaceutical giant Roche has said the low levels of Covid-19 prevalence in the UK have made it hard to find enough participants to finish their trial of an ingestible treatment for the disease.

Speaking on Wednesday, Bill Anderson, the head of Roche’s pharmaceutical division, told Reuters that it was taking longer than expected to finish their trial. The company’s chairman Christoph Franz had previously indicated results might be available before the end of March.

“There’s just simply not enough patients to enrol… with the speed we were hoping for,” Anderson stated, noting that the UK’s strict lockdown and fast vaccination program had seen infection rates plummet in the country in recent months.

“That’s been one of the challenges since the beginning of the pandemic: you set up sites where there’s a lot of Covid, and then by the time you’re ready to enrol, the pandemic has moved somewhere else and you’re sort of chasing it,” he noted, but did not disclose any candidates for new trial locations. 

Read More Here

redditpinterestlinkedintumblrmail